Experimental gastric carcinogenesis in cebus apella nonhuman primates

• Autor(a) principal: Costa, Joana de Fátima Ferreira Borges da
• Data de Publicação: 2011
• Outros Autores: Leal, Mariana Ferreira, Silva, Tanielly Cristina Raiol, Rezende, Alexandre Pingarilho, Muniz, José Augusto Pereira Carneiro, Lacreta Junior, Antonio Carlos Cunha, Assumpção, Paulo Pimentel, Calcagno, Danielle Queiroz, Demachki, Samia, Rabenhorst, Silvia Helena Barem, Smith, Marília de Arruda Cardoso, Burbano, Rommel Rodriguez
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UFLA
• Texto Completo: http://repositorio.ufla.br/jspui/handle/1/12400
• topic: Experimental Gastric; Gastric cancer; Carcinogenesis; Gastrointestinal tract; Hematology; Lymphocytes; Folic acid

The evolution of gastric carcinogenesis remains largely unknown. We established two gastric carcinogenesis models in NewWorld nonhuman primates. In the first model, ACP03 gastric cancer cell line was inoculated in 18 animals. In the second model, we treated 6 animals with N-methyl-nitrosourea (MNU). Animals with gastric cancer were also treated with Canova immunomodulator. Clinical, hematologic, and biochemical, including C-reactive protein, folic acid, and homocysteine, analyses were performed in this study. MYC expression and copy number was also evaluated. We observed that all animals inoculated with ACP03 developed gastric cancer on the 9th day though on the 14th day presented total tumor remission. In the second model, all animals developed pre-neoplastic lesions and five died of drug intoxication before the development of cancer. The last surviving MNU-treated animal developed intestinal-type gastric adenocarcinoma observed by endoscopy on the 940th day. The level of C-reactive protein level and homocysteine concentration increased while the level of folic acid decreased with the presence of tumors in ACP03-inoculated animals and MNU treatment. ACP03 inoculation also led to anemia and leukocytosis. The hematologic and biochemical results corroborate those observed in patients with gastric cancer, supporting that our in vivo models are potentially useful to study this neoplasia. In cell line inoculated animals, we detected MYC immunoreactivity, mRNA overexpression, and amplification, as previously observed in vitro. In MNU-treated animals, mRNA expression and MYC copy number increased during the sequential steps of intestinal-type gastric carcinogenesis and immunoreactivity was only observed in intestinal metaplasia and gastric cancer. Thus, MYC deregulation supports the gastric carcinogenesis process. Canova immunomodulator restored several hematologic measurements and therefore, can be applied during/after chemotherapy to increase the tolerability and duration of anticancer treatments.